Swedish Cardiac And Renal Failure Study-1

Previous studies have shown that patients with heart failure with reduced pumping function and preserved kidney function experience improved symptoms, longer survival, and fewer hospitalizations when treated with medications such as eplerenone. However, individuals with impaired kidney function have been excluded from these trials due to concerns about potential adverse effects on potassium levels, kidney function, and possibly also blood pressure. As a result, clear treatment recommendations for this high-risk group are lacking. In recent years, however, background therapies have been modernized and are now associated with a lower risk of potassium disturbances. Preliminary data also suggest that patients with impaired kidney function may benefit from eplerenone treatment. However, confirmation through dedicated studies is needed. The primary objective of this pilot trial is to assess the feasibility and safety of eplerenone in patients with heart failure with reduced pumping function and impaired kidney function. Treatment effectiveness will also be explored.

NCT Number	NCT07029503
Lead Sponsor	Karolinska Institutet
Conditions	HFrEF - Heart Failure With Reduced Ejection Fraction, Chronic Kidney Disease
Enrollment	40 participants
Start Date	2026-02
Primary Completion	2027-02 (estimated)
Study Completion	2027-10 (estimated)
Updated on ClinicalTrials.gov	2026-02-24